PrEP HIV

Effective September 30, 2024, CMS will cover pre-exposure prophylaxis (PrEP) using antiretroviral drugs approved by the U.S. Food and Drug Administration (FDA) to prevent HIV in individuals at increased risk of HIV acquisition.

Last Updated Apr 07 , 2025